A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

• Change from baseline in fasting plasma glucose; change from baseline in body weight; responder rates for HbA1c (target <=7.0%, <=6.5%); incidence of hypoglycemia; change from baseline in lipid profile. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
• Relative change in glucose, insulin, C-peptide and glucagon during a meal tolerance test. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
• Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

• Drug: insulin glargine
  starting dose 10 IU daily
• Drug: metformin
  As prescribed
• Drug: taspoglutide
  10 mg once weekly
• Drug: taspoglutide
  20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)

• Active Comparator: insulin glargine
  insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
  Interventions:

  • Drug: insulin glargine
  • Drug: metformin
• Experimental: taspoglutide 10 mg
  taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
  Interventions:

  • Drug: metformin
  • Drug: taspoglutide
• Experimental: taspoglutide 10 mg/20 mg
  taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment
  Interventions:

  • Drug: metformin
  • Drug: taspoglutide

Inclusion Criteria:

• adult patients, 18-75 years of age;
• type 2 diabetes treated with a stable dose of metformin and sulphonylurea for at least 12 weeks;
• C-peptide (fasting) >=1.0ng/mL;
• HbA1c >=7.0% and <=10.0% at screening;
• BMI >=25 (>23 for Asians) and <=45kg/m2 at screening;
• stable weight +-5% for at least 12 weeks prior to screening.

Exclusion Criteria:

• history of type 1 diabetes mellitus or acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma in the previous 6 months;
• evidence of clinically significant diabetic complications;
• symptomatic poorly controlled diabetes;
• clinically symptomatic gastrointestinal disease;
• myocardial infarction, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within the previous 6 months;
• known hemoglobinopathy or chronic anemia.